Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Lecanemab Hits PIII Mark with 27% Cut in Clinical Decline, Eisai Set for Submissions by March-End
September 29, 2022
-
ORGANIZATION Policy Veterans’ Group Proposes Simple Drug Price Maintenance Scheme for Patented Meds
September 28, 2022
-
REGULATORY Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
-
BUSINESS Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
-
REGULATORY Revamped Expert Panel Holds Industry Hearing, Discussions Center on Drug Price Gap
September 26, 2022
-
BUSINESS Janssen Aims to Rank Among Top 3 Drug Makers in Japan by 2024: Local Chief
September 22, 2022
-
REGULATORY 2 Years after Full Rollout, Sakigake System Shows Tepid Uptake as Industry Sees Poor Incentives
September 21, 2022
-
REGULATORY MHLW Retools New Expert Panel, Industry Hearing Set for Sept. 22
September 21, 2022
-
BUSINESS Boehringer Ingelheim Revamping Biz Sites in Japan to Spur Communications among Drug Reps
September 20, 2022
-
BUSINESS Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
September 16, 2022
-
BUSINESS Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
September 15, 2022
-
BUSINESS Alnylam Japan Paints Two-Digit Annual Growth Outlook on ATTR Meds and Pipeline Drugs
September 14, 2022
-
BUSINESS Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
-
REGULATORY Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
-
COMMENTARY Delving into Potential Implications of Envisaged Price Revision Overhaul
September 12, 2022
-
ORGANIZATION FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
-
BUSINESS Lagevrio’s Normal Distribution to Start from Sept. 16: MSD
September 9, 2022
-
ACADEMIA University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
September 8, 2022
-
REGULATORY Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
September 8, 2022
-
ORGANIZATION Ex-MHLW Official Isobe, Now at Self-Medication Group, Touts OTC Use to Soften Impact of Off-Year Re-Pricing
September 7, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…